Search

Your search keyword '"Patriarca A"' showing total 40 results
Start Over Author "Patriarca A" Journal leukemia
40 results on '"Patriarca A"'

1. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Author

Chiappella, Annalisa, Casadei, Beatrice, Chiusolo, Patrizia, Di Rocco, Alice, Ljevar, Silva, Magni, Martina, Angelillo, Piera, Barbui, Anna Maria, Cutini, Ilaria, Dodero, Anna, Bonifazi, Francesca, Tisi, Maria Chiara, Bramanti, Stefania, Musso, Maurizio, Farina, Mirko, Martino, Massimo, Novo, Mattia, Grillo, Giovanni, Patriarca, Francesca, Zacchi, Giulia, Krampera, Mauro, Pennisi, Martina, Galli, Eugenio, Martelli, Maurizio, Ferreri, Andrés J. M., Ferrari, Silvia, Saccardi, Riccardo, Bermema, Anisa, Guidetti, Anna, Miceli, Rosalba, Zinzani, Pier Luigi, and Corradini, Paolo

Published
2024
Full Text
View/download PDF

2. Second versus first wave of COVID-19 in patients with MPN

Author

Barbui, Tiziano, Iurlo, Alessandra, Masciulli, Arianna, Carobbio, Alessandra, Ghirardi, Arianna, Carioli, Greta, Sobas, Marta Anna, Elli, Elena Maria, Rumi, Elisa, De Stefano, Valerio, Lunghi, Francesca, Marchetti, Monia, Daffini, Rosa, Gasior Kabat, Mercedes, Cuevas, Beatriz, Fox, Maria Laura, Andrade-Campos, Marcio Miguel, Palandri, Francesca, Guglielmelli, Paola, Benevolo, Giulia, Harrison, Claire, Foncillas, Maria Angeles, Bonifacio, Massimiliano, Alvarez-Larran, Alberto, Kiladjian, Jean-Jacques, Bolaños Calderón, Estefanía, Patriarca, Andrea, Quiroz Cervantes, Keina, Griessammer, Martin, Garcia-Gutierrez, Valentin, Marin Sanchez, Alberto, Magro Mazo, Elena, Ruggeri, Marco, Hernandez-Boluda, Juan Carlos, Osorio, Santiago, Carreno-Tarragona, Gonzalo, Sagues Serrano, Miguel, Kusec, Rajko, Navas Elorza, Begona, Angona, Anna, Xicoy Cirici, Blanca, Lopez Abadia, Emma, Koschmieder, Steffen, Cattaneo, Daniele, Bucelli, Cristina, Cichocka, Edyta, Masternak Kulikowska de Nałęcz, Anna, Cavalca, Fabrizio, Borsani, Oscar, Betti, Silvia, Benajiba, Lina, Bellini, Marta, Curto-Garcia, Natalia, Rambaldi, Alessandro, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

3. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

5. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Author

Barbui, Tiziano, Vannucchi, Alessandro Maria, Alvarez-Larran, Alberto, Iurlo, Alessandra, Masciulli, Arianna, Carobbio, Alessandra, Ghirardi, Arianna, Ferrari, Alberto, Rossi, Giuseppe, Elli, Elena, Andrade-Campos, Marcio Miguel, Kabat, Mercedes Gasior, Kiladjian, Jean-Jaques, Palandri, Francesca, Benevolo, Giulia, Garcia-Gutierrez, Valentin, Fox, Maria Laura, Foncillas, Maria Angeles, Morcillo, Carmen Montoya, Rumi, Elisa, Osorio, Santiago, Papadopoulos, Petros, Bonifacio, Massimiliano, Cervantes, Keina Susana Quiroz, Serrano, Miguel Sagues, Carreno-Tarragona, Gonzalo, Sobas, Marta Anna, Lunghi, Francesca, Patriarca, Andrea, Elorza, Begona Navas, Angona, Anna, Mazo, Elena Magro, Koschmieder, Steffen, Ruggeri, Marco, Cuevas, Beatriz, Hernandez-Boluda, Juan Carlos, Abadia, Emma Lopez, Cirici, Blanca Xicoy, Guglielmelli, Paola, Garrote, Marta, Cattaneo, Daniele, Daffini, Rosa, Cavalca, Fabrizio, Bellosillo, Beatriz, Benajiba, Lina, Curto-Garcia, Natalia, Bellini, Marta, Betti, Silvia, De Stefano, Valerio, Harrison, Claire, and Rambaldi, Alessandro

Published
2021
Full Text
View/download PDF

6. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index

Author

Efficace, Fabio, Cottone, Francesco, Oswald, Laura B., Cella, David, Patriarca, Andrea, Niscola, Pasquale, Breccia, Massimo, Platzbecker, Uwe, Palumbo, Giuseppe A., Caocci, Giovanni, Stauder, Reinhard, Ricco, Alessandra, Petranovic, Duska, Caers, Jo, Luppi, Mario, Fianchi, Luana, Frairia, Chiara, Capodanno, Isabella, Follini, Elena, Sarlo, Chiara, Fazi, Paola, and Vignetti, Marco

Published
2020
Full Text
View/download PDF

7. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

Author

Efficace, Fabio, Stagno, Fabio, Iurlo, Alessandra, Breccia, Massimo, Cottone, Francesco, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Castagnetti, Fausto, Caocci, Giovanni, Crugnola, Monica, Capodanno, Isabella, Martino, Bruno, Tiribelli, Mario, Patriarca, Andrea, Gozzini, Antonella, Pregno, Patrizia, Saussele, Susanne, Cascavilla, Nicola, Fozza, Claudio, Bergamaschi, Micaela, Binotto, Gianni, Vignetti, Marco, and Rosti, Gianantonio

Published
2020
Full Text
View/download PDF

8. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Author

Barbui, Tiziano, Ghirardi, Arianna, Masciulli, Arianna, Carobbio, Alessandra, Palandri, Francesca, Vianelli, Nicola, De Stefano, Valerio, Betti, Silvia, Di Veroli, Ambra, Iurlo, Alessandra, Cattaneo, Daniele, Delaini, Federica, Bonifacio, Massimiliano, Scaffidi, Luigi, Patriarca, Andrea, Rumi, Elisa, Casetti, Ilaria Carola, Stephenson, Clemency, Guglielmelli, Paola, Elli, Elena Maria, Palova, Miroslava, Bertolotti, Laura, Erez, Daniel, Gomez, Montse, Wille, Kai, Perez-Encinas, Manuel, Lunghi, Francesca, Angona, Anna, Fox, Maria Laura, Beggiato, Eloise, Benevolo, Giulia, Carli, Giuseppe, Cacciola, Rossella, McMullin, Mary Frances, Tieghi, Alessia, Recasens, Valle, Marchetti, Monia, Griesshammer, Martin, Alvarez-Larran, Alberto, Vannucchi, Alessandro Maria, and Finazzi, Guido

Published
2019
Full Text
View/download PDF

10. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Abstract

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n= 274) or with (n= 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p= 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p= 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p= 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p= 0.03) and HLA mismatch donor (p= 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

Published
2024
Full Text
View/download PDF

11. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Author

Gay, F, Oliva, S, Petrucci, M T, Montefusco, V, Conticello, C, Musto, P, Catalano, L, Evangelista, A, Spada, S, Campbell, P, Ria, R, Salvini, M, Offidani, M, Carella, A M, Omedé, P, Liberati, A M, Troia, R, Cafro, A M, Malfitano, A, Falcone, A P, Caravita, T, Patriarca, F, Nagler, A, Spencer, A, Hajek, R, Palumbo, A, and Boccadoro, M

Published
2017
Full Text
View/download PDF

13. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

Author

Zamagni, E, Nanni, C, Gay, F, Pezzi, A, Patriarca, F, Bellò, M, Rambaldi, I, Tacchetti, P, Hillengass, J, Gamberi, B, Pantani, L, Magarotto, V, Versari, A, Offidani, M, Zannetti, B, Carobolante, F, Balma, M, Musto, P, Rensi, M, Mancuso, K, Dimitrakopoulou-Strauss, A, Chauviè, S, Rocchi, S, Fard, N, Marzocchi, G, Storto, G, Ghedini, P, Palumbo, A, Fanti, S, and Cavo, M

Published
2016
Full Text
View/download PDF

14. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Author

Rosa Daffini, Gonzalo Carreño-Tarragona, Paola Guglielmelli, Arianna Masciulli, Maria Laura Fox, Claire N. Harrison, Daniele Cattaneo, Beatriz Bellosillo, Petros Papadopoulos, Beatriz Cuevas, Maria Angeles Foncillas, Anna Angona, Alberto Ferrari, Valentín García-Gutiérrez, Arianna Ghirardi, Andrea Patriarca, Elena Maria Elli, Juan Carlos Hernández-Boluda, Tiziano Barbui, Silvia Betti, Valerio De Stefano, Giuseppe Rossi, Marta Bellini, Carmen Montoya Morcillo, Marta Sobas, Miguel Sagues Serrano, Fabrizio Cavalca, Lina Benajiba, Francesca Palandri, Emma Lopez Abadia, Marta Garrote, Alberto Alvarez-Larrán, Natalia Curto-Garcia, Mercedes Gasior Kabat, Alessandra Carobbio, Marcio Andrade-Campos, Francesca Lunghi, Marco Ruggeri, Jean-Jaques Kiladjian, Begona Navas Elorza, Elena Magro Mazo, Elisa Rumi, Giulia Benevolo, Alessandro Rambaldi, Alessandra Iurlo, Blanca Xicoy Cirici, Alessandro M. Vannucchi, Keina Susana Quiroz Cervantes, Massimiliano Bonifacio, Steffen Koschmieder, and Santiago Osorio

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Ruxolitinib, Population, Article, Myeloproliferative disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Risk of mortality, Medicine, education, Myelofibrosis, Survival rate, education.field_of_study, Univariate analysis, business.industry, Essential thrombocythemia, Mortality rate, Hematology, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Infectious diseases, business, medicine.drug
Abstract

We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p=0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.

Published
2021
Full Text
View/download PDF

15. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, Forcina, A, Clerici, D, Crocchiolo, R, Vago, L, Stanghellini, M T L, Noviello, M, Messina, C, Crotta, A, Assanelli, A, Marktel, S, Olek, S, Mastaglio, S, Giglio, F, Crucitti, L, Lorusso, A, Guggiari, E, Lunghi, F, Carrabba, M, Tassara, M, Battaglia, M, Ferraro, A, Carbone, M R, Oliveira, G, Roncarolo, M G, Rossini, S, Bernardi, M, Corti, C, Marcatti, M, Patriarca, F, Zecca, M, Locatelli, F, Bordignon, C, Fleischhauer, K, Bondanza, A, Bonini, C, and Ciceri, F

Published
2015
Full Text
View/download PDF

16. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

Author

Marco Vignetti, Antonella Gozzini, Andrea Patriarca, Fausto Castagnetti, Massimo Breccia, Alessandra Iurlo, Monica Crugnola, Elisabetta Abruzzese, Bruno Martino, Claudio Fozza, Nicola Cascavilla, Gianni Binotto, Giovanni Caocci, Massimiliano Bonifacio, I Capodanno, Fabio Stagno, Patrizia Pregno, Micaela Bergamaschi, Francesco Cottone, Fabio Efficace, Mario Tiribelli, Gianantonio Rosti, Susanne Saussele, Efficace F., Stagno F., Iurlo A., Breccia M., Cottone F., Bonifacio M., Abruzzese E., Castagnetti F., Caocci G., Crugnola M., Capodanno I., Martino B., Tiribelli M., Patriarca A., Gozzini A., Pregno P., Saussele S., Cascavilla N., Fozza C., Bergamaschi M., Binotto G., Vignetti M., and Rosti G.

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, chronic myeloid leukemia, health-related quality of life, tyrosine kinase inhibitors, EORTC QLQ, Antineoplastic Agents, 03 medical and health sciences, 0302 clinical medicine, Quality of life, chronic myeloid leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, medicine, Humans, dasatinib, Protein Kinase Inhibitors, Aged, business.industry, Case-control study, Myeloid leukemia, Cancer, chronic myeloid leukemia,imatinib,dasatinib,quality of life, Imatinib, Hematology, Middle Aged, medicine.disease, humanities, Clinical trial, Dasatinib, 030104 developmental biology, imatinib, quality of life, Case-Control Studies, 030220 oncology & carcinogenesis, Imatinib Mesylate, Female, Patient-reported outcome, business, medicine.drug
Abstract

There is paucity of evidence-based data on health-related quality of life (HRQOL) outcomes of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We performed a multicenter propensity-matched case-control study to compare HRQOL of newly diagnosed CML patients treated with front-line dasatinib (cases) or imatinib (controls). Patient-reported HRQOL was assessed with the EORTC QLQ-C30 and the EORTC QLQ-CML24 questionnaires. The impact on daily life scale of the EORTC QLQ-CML24 was selected a priori in the protocol as the primary HRQOL scale for the comparative analysis. Overall, 323 CML patients were enrolled of whom 223 in therapy with imatinib and 100 in therapy with dasatinib. Patients treated with dasatinib reported better disease-specific HRQOL outcomes in impact on daily life (Δ = 8.72, 95% confidence interval [CI]: 3.17-14.27, p = 0.002), satisfaction with social life (Δ = 13.45, 95% CI: 5.82-21.08, p = 0.001), and symptom burden (Δ = 7.69, 95% CI: 3.42-11.96, p = 0.001). Analysis by age groups showed that, in patients aged 60 years and over, differences favoring dasatinib were negligible across several cancer generic and disease-specific HRQOL domains. Our findings provide novel comparative HRQOL data that extends knowledge on safety and efficacy of these two TKIs and may help to facilitate first-line treatment decisions.

Published
2019
Full Text
View/download PDF

17. Second versus first wave of COVID-19 in patients with MPN

Author

Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Anna Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Maria Laura Fox, Marcio Miguel Andrade-Campos, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Andrea Patriarca, Keina Quiroz Cervantes, Martin Griessammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Elena Magro Mazo, Marco Ruggeri, Juan Carlos Hernandez-Boluda, Santiago Osorio, Gonzalo Carreno-Tarragona, Miguel Sagues Serrano, Rajko Kusec, Begona Navas Elorza, Anna Angona, Blanca Xicoy Cirici, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak Kulikowska de Nałęcz, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Lina Benajiba, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, and Alessandro Maria Vannucchi

Subjects
Cancer Research, COVID-19 / virology, Myeloproliferative Disorders, SARS-CoV-2, COVID-19, Hematology, SARS-CoV-2 / isolation & purification, Survival Analysis, Myeloproliferative disease, COVID-19 / mortality, Oncology, Risk Factors, Myeloproliferative Disorders / complications, Correspondence, Humans, Infectious diseases, COVID-19 / complications
Published
2021

23. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

Author

Corradini, P, Dodero, A, Farina, L, Fanin, R, Patriarca, F, Miceli, R, Matteucci, P, Bregni, M, Scimè, R, Narni, F, Pogliani, E, Locasciulli, A, Milani, R, Carniti, C, Bacigalupo, A, Rambaldi, A, Bonifazi, F, Olivieri, A, Gianni, A M, and Tarella, C

Published
2007
Full Text
View/download PDF

25. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Author

Todisco, E, Ciceri, F, Oldani, E, Boschini, C, Micò, C, VanLint, M T, Donnini, I, Patriarca, F, Alessandrino, P E, Bonifazi, F, Arcese, W, Barberi, W, Marenco, P, Terruzzi, E, Cortelazzo, S, Santarone, S, Proia, A, Corradini, P, Tagliaferri, E, Falcioni, S, Irrera, G, Dallanegra, L, Castagna, L, Santoro, A, Camboni, A, Sacchi, N, Bosi, A, Bacigalupo, A, and Rambaldi, A

Published
2013
Full Text
View/download PDF

27. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Author

Barbui, T., Ghirardi, A., Vannucchi, A. M., Marchetti, M., De Stefano, Valerio, Masciulli, A., Carobbio, A., Palandri, F., Vianelli, N., Betti, S., Di Veroli, A., Iurlo, A., Cattaneo, D., Finazzi, G., Bonifacio, M., Scaffidi, L., Patriarca, A., Rumi, E., Casetti, I. C., Stephenson, C., Guglielmelli, P., Elli, E. M., Palova, M., Bertolotti, L., Erez, D., Gomez, M., Wille, K., Perez-Encinas, M., Lunghi, F., Angona, A., Fox, M. L., Beggiato, E., Benevolo, G., Carli, G., Cacciola, R., Mcmullin, M. F., Tieghi, A., Recasens, V., Isfort, S., Griesshammer, M., Alvarez-Larran, A., and Rambaldi, A.

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Aspirin, business.industry, Hematology, Second primary cancer, Settore MED/15 - MALATTIE DEL SANGUE, Internal medicine, medicine, business, Myelopriferative neoplasms, medicine.drug
Published
2019
Full Text
View/download PDF

28. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy

Author

Efficace, Fabio, primary, Stagno, Fabio, additional, Iurlo, Alessandra, additional, Breccia, Massimo, additional, Cottone, Francesco, additional, Bonifacio, Massimiliano, additional, Abruzzese, Elisabetta, additional, Castagnetti, Fausto, additional, Caocci, Giovanni, additional, Crugnola, Monica, additional, Capodanno, Isabella, additional, Martino, Bruno, additional, Tiribelli, Mario, additional, Patriarca, Andrea, additional, Gozzini, Antonella, additional, Pregno, Patrizia, additional, Saussele, Susanne, additional, Cascavilla, Nicola, additional, Fozza, Claudio, additional, Bergamaschi, Micaela, additional, Binotto, Gianni, additional, Vignetti, Marco, additional, and Rosti, Gianantonio, additional

Published
2019
Full Text
View/download PDF

29. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Author

Stefano Spada, Mario Boccadoro, Roberto Mina, Angelo Belotti, Giuseppe Rossi, Lorenzo De Paoli, Rossella Troia, Antonio Palumbo, Alessandra Lombardo, Anna Marina Liberati, Sara Bringhen, Anna Maria Cafro, Pieter Sonneveld, Francesca Patriarca, Renato Fanin, Gianluca Gaidano, Paola Bertazzoni, and Hematology

Subjects
Oncology, medicine.medical_specialty, Cancer Research, Dexamethasone, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Hematology, Anesthesiology and Pain Medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival rate, Multiple myeloma, business.industry, Low dose, Follow-Up Studies, Multiple Myeloma, Oligopeptides, Prognosis, Survival Rate, Thalidomide, medicine.disease, Pomalidomide, Carfilzomib, chemistry, 030220 oncology & carcinogenesis, Relapsed refractory, business, 030215 immunology, medicine.drug
Published
2017

30. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

Author

S. A. Pileri, Anna Dodero, Umberto Vitolo, Francesco Benedetti, Benedetto Bruno, Giulio Rossi, Anna Ferreri, Andrea Gallamini, Flavia Salvi, Paolo Corradini, Corrado Tarella, Luca Baldini, Attilio Olivieri, Caterina Patti, Francesca Patriarca, Giuseppe Todeschini, Alessandro Rambaldi, and Rosalba Miceli

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Vincristine, Lymphoma, Cyclophosphamide, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, CHOP, Disease-Free Survival, Peripheral, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Proportional Hazards Models, business.industry, Hematopoietic Stem Cell Transplantation, Lymphoma, T-Cell, Peripheral, Hematology, Middle Aged, T-Cell, Prognosis, medicine.disease, Combined Modality Therapy, Peripheral T-cell lymphoma, Surgery, Transplantation, Alemtuzumab, Female, Immunotherapy, business, medicine.drug
Abstract

Peripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemo-immunotherapy in young (⩽60 years old, Clin A study) and elderly (60 andor =75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.

Published
2014
Full Text
View/download PDF

31. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

Author

Mario Boccadoro, Luisa Giaccone, Daniela Drandi, Marco Ladetto, Nicola Mordini, Antonio Palumbo, Benedetto Bruno, Guglielmo Guarona, Paola Omedè, Moreno Festuccia, Silvia Cena, Roberto Passera, Federica Ferrando, R Fanin, Francesca Patriarca, Lucia Brunello, V Boccasavia, R Benedetto, Simone Ferrero, and Paola Ghione

Subjects
Cancer Research, medicine.medical_specialty, Neoplasm, Residual, Transplantation Conditioning, medicine.medical_treatment, Hematopoietic stem cell transplantation, Newly diagnosed, Real-Time Polymerase Chain Reaction, 03 medical and health sciences, 0302 clinical medicine, Recurrence, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Transplantation, Homologous, Prospective Studies, Prospective cohort study, Multiple myeloma, business.industry, Hematopoietic Stem Cell Transplantation, Non myeloablative, Hematology, medicine.disease, Minimal residual disease, Surgery, Transplantation, surgical procedures, operative, Oncology, 030220 oncology & carcinogenesis, Radiology, business, Multiple Myeloma, 030215 immunology
Abstract

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

Published
2015

32. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

Author

Gay, F, primary, Oliva, S, additional, Petrucci, M T, additional, Montefusco, V, additional, Conticello, C, additional, Musto, P, additional, Catalano, L, additional, Evangelista, A, additional, Spada, S, additional, Campbell, P, additional, Ria, R, additional, Salvini, M, additional, Offidani, M, additional, Carella, A M, additional, Omedé, P, additional, Liberati, A M, additional, Troia, R, additional, Cafro, A M, additional, Malfitano, A, additional, Falcone, A P, additional, Caravita, T, additional, Patriarca, F, additional, Nagler, A, additional, Spencer, A, additional, Hajek, R, additional, Palumbo, A, additional, and Boccadoro, M, additional

Published
2016
Full Text
View/download PDF

33. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Author

Almalina Bacigalupo, P E Alessandrino, Paolo Corradini, Elisabetta Todisco, Elena Tagliaferri, Stella Santarone, Giuseppe Irrera, Sadia Falcioni, Sergio Cortelazzo, Anna Proia, L Dallanegra, Walter Barberi, Luca Castagna, Armando Santoro, Nicoletta Sacchi, Paola Marenco, Elisabetta Terruzzi, Alessandro Rambaldi, Elena Oldani, Cristina Boschini, M T Van-Lint, Francesca Bonifazi, Caterina Micò, Fabio Ciceri, Alberto Bosi, A Camboni, Irene Donnini, William Arcese, and Francesca Patriarca

Subjects
Myeloid, Homologous, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Allogeneic transplantation, Transplantation Conditioning, Adolescent, Acute, Young Adult, Internal medicine, Active disease, Retrospective analysis, Medicine, Humans, Transplantation, Homologous, Young adult, Survival rate, Letter to the Editor, Aged, Retrospective Studies, Transplantation, Leukemia, business.industry, Retrospective cohort study, Hematology, Middle Aged, Settore MED/15, Prognosis, humanities, Surgery, Survival Rate, Leukemia, Myeloid, Acute, Reduced Intensity Conditioning, Female, Follow-Up Studies, Stem Cell Transplantation, business
Abstract

The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo

Published
2013

34. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

Author

Mario Boccadoro, Dina Ben-Yehuda, Pellegrino Musto, Elisabetta Calabrese, Antonio Palumbo, M.T. Petrucci, Nicola Cascavilla, A. M. Cafro, Arnon Nagler, Francesca Patriarca, Anna Marina Liberati, Barbara Lupo, Giuseppe Milone, Fausto Rossini, Claudia Crippa, Roberto Passera, Vittorio Montefusco, Paola Omedè, Sara Bringhen, Federica Cavallo, Jacopo Peccatori, Tommaso Caravita, Lucio Catalano, and A. M. Carella

Subjects
Oncology, novel agent, Male, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, Antineoplastic Agents, Autologous stem-cell transplantation, Internal medicine, Medicine, Autologous transplantation, Humans, mobilization, Lenalidomide, Hematopoietic Stem Cell Mobilization, Multiple myeloma, business.industry, Hematology, Middle Aged, medicine.disease, Surgery, Thalidomide, Transplantation, myeloma, lenalidomide, transplantation, Female, Stem cell, business, medicine.drug
Abstract

Lenalidomide has raised concerns regarding its potential impact on the ability to collect stem cells for autologous stem cell transplantation, especially after prolonged exposure. The use of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) to mobilize peripheral blood stem cells may overcome this concern. In newly diagnosed multiple myeloma (MM) patients, we investigated the influence of lenalidomide on stem cell collection. In a prospective study, 346 patients received four cycles of lenalidomide-dexamethasone (Rd). Stem cells were mobilized with cyclophosphamide and G-CSF. Patients failing to collect a minimum of 4 × 10(6) CD34(+)/kg cells received a second mobilization course. After mobilization, a median yield of 8.7 × 10(6) CD34(+)/kg was obtained from patients receiving Rd induction. After first mobilization, inadequate yield was observed in 21% of patients, whereas only 9% of patients failed to collect the target yield after the second mobilization attempt. In conclusion, we confirm that a short induction with lenalidomide allowed sufficient stem cells collection to perform autologous transplantation in 91% of newly diagnosed patients.

Published
2011

35. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease

Author

Zamagni, E, primary, Nanni, C, additional, Gay, F, additional, Pezzi, A, additional, Patriarca, F, additional, Bellò, M, additional, Rambaldi, I, additional, Tacchetti, P, additional, Hillengass, J, additional, Gamberi, B, additional, Pantani, L, additional, Magarotto, V, additional, Versari, A, additional, Offidani, M, additional, Zannetti, B, additional, Carobolante, F, additional, Balma, M, additional, Musto, P, additional, Rensi, M, additional, Mancuso, K, additional, Dimitrakopoulou-Strauss, A, additional, Chauviè, S, additional, Rocchi, S, additional, Fard, N, additional, Marzocchi, G, additional, Storto, G, additional, Ghedini, P, additional, Palumbo, A, additional, Fanti, S, additional, and Cavo, M, additional

Published
2015
Full Text
View/download PDF

36. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma

Author

Ladetto, M, primary, Ferrero, S, additional, Drandi, D, additional, Festuccia, M, additional, Patriarca, F, additional, Mordini, N, additional, Cena, S, additional, Benedetto, R, additional, Guarona, G, additional, Ferrando, F, additional, Brunello, L, additional, Ghione, P, additional, Boccasavia, V, additional, Fanin, R, additional, Omedè, P, additional, Giaccone, L, additional, Palumbo, A, additional, Passera, R, additional, Boccadoro, M, additional, and Bruno, B, additional

Published
2015
Full Text
View/download PDF

37. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation

Author

Paolo Corradini, Roberto Sorasio, Francesca Patriarca, Lucia Farina, Renato Fanin, Mara Morelli, Benedetto Bruno, Mario Boccadoro, and Francesco Spina

Subjects
Oncology, Adult, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Lymphoma, Comorbidity, Young Adult, HLA Antigens, Predictive Value of Tests, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Karnofsky Performance Status, Survival analysis, Multiple myeloma, Aged, Retrospective Studies, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Total body irradiation, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Surgery, Transplantation, Regimen, Treatment Outcome, Multivariate Analysis, business, Multiple Myeloma
Abstract

The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to identify patients at high risk of mortality after an allograft. Reduced-intensity/non-myeloablative regimens have decreased the non-relapse mortality (NRM) in elderly and/or heavily pretreated patients. We performed a retrospective study to assess whether HCT-CI may predict clinical outcomes in a cohort of 203 patients with non-Hodgkin's (NHL; n=108), Hodgkin's lymphomas (HL; n=26), and multiple myeloma (MM; n=69), who were transplanted from a human leucocyte antigen (HLA)-matched sibling (n=121) or an unrelated donor (n=82) after a reduced-intensity regimen (n=154) or a low-dose total body irradiation-based non-myeloblative regimen (n=49). Cumulative incidence of NRM was 5, 16 and 20% at 1 year and 6, 24 and 27% at 2 years, for patients with an HCT-CI of 0, 1-2 and > or =3, respectively. By multivariate analysis, HCT-CI significantly predicted NRM (hazard ratio (HR)=1.6, P=0.03), overall survival (OS; HR=1.62, P

Published
2009

38. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

Author

Peccatori, J, primary, Forcina, A, additional, Clerici, D, additional, Crocchiolo, R, additional, Vago, L, additional, Stanghellini, M T L, additional, Noviello, M, additional, Messina, C, additional, Crotta, A, additional, Assanelli, A, additional, Marktel, S, additional, Olek, S, additional, Mastaglio, S, additional, Giglio, F, additional, Crucitti, L, additional, Lorusso, A, additional, Guggiari, E, additional, Lunghi, F, additional, Carrabba, M, additional, Tassara, M, additional, Battaglia, M, additional, Ferraro, A, additional, Carbone, M R, additional, Oliveira, G, additional, Roncarolo, M G, additional, Rossini, S, additional, Bernardi, M, additional, Corti, C, additional, Marcatti, M, additional, Patriarca, F, additional, Zecca, M, additional, Locatelli, F, additional, Bordignon, C, additional, Fleischhauer, K, additional, Bondanza, A, additional, Bonini, C, additional, and Ciceri, F, additional

Published
2014
Full Text
View/download PDF

39. Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias

Author

Agostino Cortelezzi, Maria Goldaniga, Daniela Intini, A. Guffanti, M.G. Grimoldi, C Patriarca, Mariangela Colombi, L. Cro, Luca Baldini, Antonino Neri, Anna Teresa Maiolo, and Bruno Mario Cesana

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Chronic lymphocytic leukemia, Mature B-Cell, Blotting, Western, Immunoglobulins, CD5 Antigens, Sensitivity and Specificity, Prognostic stratification, Immunophenotyping, Antigens, CD, Lectins, Proto-Oncogene Proteins, Medicine, Humans, Lymphocytes, Aged, Aged, 80 and over, Chromosome Aberrations, business.industry, Receptors, IgE, Membrane Proteins, Hematology, Middle Aged, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Genes, bcl-1, DNA-Binding Proteins, Gene Expression Regulation, Neoplastic, Survival Rate, Oncology, Karyotyping, Proto-Oncogene Proteins c-bcl-6, Female, business, Follow-Up Studies, Transcription Factors
Abstract

We verified the diagnostic and prognostic role of a simplified immunophenotypic classification (IC) in a series of 258 patients (M/F: 1.4; median age: 64 years; median follow-up: 64 months; 75 deaths) with mature B cell lymphoid leukemias (MBC-LL) for whom no histopathological diagnosis was available because of minimal or no lymph node involvement. The IC was based on the reactivity of three pivotal immunophenotypic markers: CD5, CD23 and SIg intensity. On the basis of different expression patterns, we identified four diagnostic clusters (C) characterized by distinct clinico-biological features and different prognoses: C1 (149 patients) identified most classical B cell chronic lymphocytic leukemias (CLL-type cluster; SIg(dim)/CD5+/CD23+); C2, 38 patients whose clinico-hematological characteristics were intermediate between C1 and C3 (CLL-variant cluster; SIg(bright)/CD5+/CD23+/-or SIg(dim)/CD5-/-/CD23 indifferent); C3 (16 patients) most situations consistent with mantle cell lymphoma in leukemic phase (MCL-type cluster; SIg(bright)/CD5+/CD23-); and C4, 55 cases, most of whom were consistent with leukemic phase lymphoplasmacytic/splenic marginal zone lymphomas (LP/S-type cluster; SIg(bright)/CD5-/+/CD23 indifferent). At univariate survival analysis, prognosis worsened from C1 to C4, C2 and C3 (P = 0.0001), and this was maintained at multivariate analysis (P = 0.006), together with CD11c expression (P = 0.0043), age at diagnosis (cut-off 70 years; P = 0.0008) and platelet count (cut-off 140 x 10(9)/l; P = 0.0034). Besides recognising the two well-known situations of classic B-CLL and MCL, our IC identified situations with distinct prognostic and/or clinical behaviors.

Published
2002

40. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect

Author

Dodero, A, primary, Spina, F, additional, Narni, F, additional, Patriarca, F, additional, Cavattoni, I, additional, Benedetti, F, additional, Ciceri, F, additional, Baronciani, D, additional, Scimè, R, additional, Pogliani, E, additional, Rambaldi, A, additional, Bonifazi, F, additional, Dalto, S, additional, Bruno, B, additional, and Corradini, P, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results